Ori Biotech Raises Over USD100M in Series B Funding

Ori Biotech Ltd., a London, UK- and and New Jersey-based leader in cell and gene therapy (CGT) manufacturing technology, secured over USD 100m in Series B funding.

The round was led by Novalis LifeSciences with participation from Puhua Capital and Chimera Abu Dhabi and existing investors Amadeus Capital Partners, Delin Ventures, Northpond Ventures and Octopus Ventures.

The company will use the funds to further expand key personnel across all functions, in order to transition through pre-commercialization to the launch of its innovative CGT manufacturing platform. It is also launching its Lightspeed Early Access Program (LEAP), allowing select partners to gain pre-launch access to the platform in 2022.

Founded in 2015 by Dr Farlan Veraitch (UCL) and led by Jason C. Foster, CEO, Ori provides a proprietary, full stack manufacturing system that closes, automates, digitizes and standardizes CGT manufacturing. It will enable therapy developers, contract manufacturers and academic researchers to transition from pre-clinical process discovery through clinical trials to commercial scale.

The management team also includes:

  • CBO Jason Jones (Miltenyi),
  • CDOO Kevin Gordon (Tmunity),
  • CTO Stuart Milne (Cytiva),
  • VP Tom Heathman (Minaris),
  • VP David Smith (Minaris),
  • VP Lee Unroe (Indivior),
  • Chris Mason (AVROBIO),
  • Paul Meister (ThermoFisher), and
  • Annalisa Jenkins (Dimension Therapeutics).